Royalty Pharma
RPRX
487 hedge funds and large institutions have $11.6B invested in Royalty Pharma in 2025 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 206 increasing their positions, 131 reducing their positions, and 53 closing their positions.
440% more call options, than puts
Call options by funds: $50.3M | Put options by funds: $9.31M
74% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 53
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
57% more repeat investments, than reductions
Existing positions increased: 206 | Existing positions reduced: 131
7% more funds holding
Funds holding: 455 → 487 (+32)
5.29% less ownership
Funds ownership: 81.34% → 76.05% (-5.3%)
6% less capital invested
Capital invested by funds: $12.4B → $11.6B (-$760M)
Top Buyers
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$921M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$448M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$93.6M |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$89M |
| 5 |
Morgan Stanley
New York
|
-$88.3M |
RPRX Hedge Fund Activity: Q3 2025 in Review
487 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2025, worth a combined $11.6B — down 6.2% from $12.4B a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new RPRX positions and 53 closed out — a net gain of 39 holders — while 206 added to existing stakes and 131 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $216M. The largest seller was Vanguard Group, cutting an estimated $921M.
- 487 institutional investors held Royalty Pharma (RPRX) as of Q3 2025, up from 455 in Q2 2025.
- Funds reported $11.6B of Royalty Pharma stock for Q3 2025, down 6.2% quarter-over-quarter.
- 92 funds opened new Royalty Pharma positions in Q3 2025 and 53 closed out, a net change of +39 holders.
- The largest Royalty Pharma buyer in Q3 2025 was Adage Capital Partners, an estimated $216M added.
- The largest Royalty Pharma seller in Q3 2025 was Vanguard Group, an estimated $921M sold.
Based on aggregated 13F filings for Q3 2025.